224 related articles for article (PubMed ID: 16467018)
21. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
[TBL] [Abstract][Full Text] [Related]
23. Puerto Rico psoriasis study group: efficacy and safety of etanercept.
González-Chavez JR; Berlingeri-Ramos AC; Sánchez Casiano MA
J Drugs Dermatol; 2005; 4(6):735-9. PubMed ID: 16302559
[TBL] [Abstract][Full Text] [Related]
24. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
25. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
Leonardi C; Strober B; Gottlieb AB; Elewski BE; Ortonne JP; van de Kerkhof P; Chiou CF; Dunn M; Jahreis A
J Drugs Dermatol; 2010 Aug; 9(8):928-37. PubMed ID: 20684143
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.
Nestorov I; Zitnik R; DeVries T; Nakanishi AM; Wang A; Banfield C
Br J Clin Pharmacol; 2006 Oct; 62(4):435-45. PubMed ID: 16995864
[TBL] [Abstract][Full Text] [Related]
28. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.
Daudén E; Griffiths CE; Ortonne JP; Kragballe K; Molta CT; Robertson D; Pedersen R; Estojak J; Boggs R
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1374-82. PubMed ID: 19563497
[TBL] [Abstract][Full Text] [Related]
29. Etanercept: efficacy and safety.
Jiménez-Puya R; Gómez-García F; Amorrich-Campos V; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):402-5. PubMed ID: 19210697
[TBL] [Abstract][Full Text] [Related]
30. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
31. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
32. Long-term etanercept in pediatric patients with plaque psoriasis.
Paller AS; Siegfried EC; Eichenfield LF; Pariser D; Langley RG; Creamer K; Kricorian G
J Am Acad Dermatol; 2010 Nov; 63(5):762-8. PubMed ID: 20605256
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
[TBL] [Abstract][Full Text] [Related]
34. Treatment of erythrodermic psoriasis with etanercept.
Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
[TBL] [Abstract][Full Text] [Related]
35. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept.
Ortonne JP; Taïeb A; Ormerod AD; Robertson D; Foehl J; Pedersen R; Molta C; Freundlich B
Br J Dermatol; 2009 Nov; 161(5):1190-5. PubMed ID: 19566665
[TBL] [Abstract][Full Text] [Related]
36. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
37. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.
Campione E; Mazzotta A; Paternò EJ; Diluvio L; Prinz JC; Chimenti S
Acta Derm Venereol; 2009; 89(3):288-91. PubMed ID: 19479128
[TBL] [Abstract][Full Text] [Related]
38. Our experience with etanercept in the treatment of psoriasis.
Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G
Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738
[TBL] [Abstract][Full Text] [Related]
39. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
Gottlieb AB; Leonardi CL; Goffe BS; Ortonne JP; van der Kerkhof PC; Zitnik R; Nakanishi A; Jahreis A
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S92-100. PubMed ID: 16488335
[TBL] [Abstract][Full Text] [Related]
40. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
